Compare · MDLN vs QNRX
MDLN vs QNRX
Side-by-side comparison of Medline Inc. (MDLN) and Quoin Pharmaceuticals Ltd. (QNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and QNRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.16B, about 3530.4x QNRX ($13.1M).
- QNRX has been more active in the news (7 items in the past 4 weeks vs 5 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 0 for QNRX).
- Company
- Medline Inc.
- Quoin Pharmaceuticals Ltd.
- Price
- $35.12+0.29%
- $6.54+2.75%
- Market cap
- $46.16B
- $13.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 0
QNRX
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest QNRX
- Director Langer Dennis was granted 34,534 units of ADSs, increasing direct ownership by 159% to 56,243 units (SEC Form 4)
- Director Culverwell Anthony James was granted 31,352 units of ADSs, increasing direct ownership by 1,094% to 34,218 units (SEC Form 4)
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
- Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events
- Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
- SEC Form DEF 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome